TIDMPRTC
RNS Number : 4120W
PureTech Health PLC
17 April 2019
17 April 2019
PureTech Health plc
PureTech Health Announces Collaboration with Boehringer
Ingelheim to Advance Immuno-oncology Product Candidates using its
Lymphatic Targeting Platform
PureTech Health to receive up to $26 million in upfront
payments, research support, and preclinical milestones and is
eligible to potentially receive more than $200 million in
milestones, in addition to royalties
Collaboration will initially focus on developing Boehringer
Ingelheim's novel immuno-oncology product candidates
PureTech Health plc (LSE: PRTC) ("PureTech Health"), an advanced
biopharmaceutical company developing novel medicines for
dysfunctions of the Brain-Immune-Gut (BIG) axis, today announced
that it has entered into a research collaboration with Boehringer
Ingelheim to develop novel product candidates for an undisclosed
number of targets by leveraging PureTech's proprietary lymphatic
targeting technology for immune modulation. Under terms of the
agreement, PureTech Health will receive up to $26 million,
including upfront payments, research support, and preclinical
milestones, and is eligible to receive more than $200 million in
development and sales milestones, in addition to royalties on
product sales. The collaboration will initially focus on applying
PureTech's lymphatic targeting technology to an immuno-oncology
product candidate designated by Boehringer Ingelheim.
"We see great promise in leveraging PureTech's platform to
target the lymphatic system and deliver therapeutic candidates
directly to the lymph nodes responsible for priming, educating and
proliferating immune cells," said Clive Wood, PhD, global head of
discovery research at Boehringer Ingelheim. "The approach is a
potentially powerful tool for modulating the immune system and may
allow us to improve efficacy and reduce systematic toxicities
through precise targeting."
The partnership leverages the potential of the proprietary
lymphatic targeting platform that PureTech Health is developing
through its internal R&D division. The approach harnesses the
gut's lipid transport mechanisms to enable oral administration and
transport of drug candidates directly through the gut-draining
lymphatic vasculature, also bypassing first pass metabolism in the
liver. More specifically, the therapeutic candidates are directed
to the mesenteric lymph nodes, which program as many as 70 per cent
of circulating adaptive immune cells. By targeting the lymphatic
system directly, the technology has the potential to achieve more
effective and precise immunomodulation of local tissues, while
sparing the patient from the risks of extensive systemic exposure
to the drug. PureTech's lymphatic targeting approach, which is
based on the research of Chris Porter, PhD, Director of the Monash
Institute of Pharmaceutical Sciences (MIPS) at Monash University,
can potentially be applied to therapeutic molecules across a range
of physiochemical properties and holds promise for the development
of novel therapeutics for gastrointestinal, central nervous system,
and autoimmune diseases as well as cancer.
"This collaboration signals the exciting potential of another
proprietary platform from our internal R&D to enable novel
immunotherapy approaches by harnessing the lymphatic system's
capacity for immune cell trafficking and immunomodulation," said
Daphne Zohar, co-founder and chief executive officer of PureTech
Health. "We look forward to working with the excellent scientific
teams at Boehringer Ingelheim to advance this important program,
which has the potential to greatly expand therapeutic options for
patients with cancer."
The research collaboration with Boehringer Ingelheim will focus
first on using this approach to administer an immuno-oncology
candidate for gastrointestinal (GI) cancers directly to the gut
lymphatics. About 70 per cent of immune cells reside in lymphatic
tissues associated with the GI tract, so targeting immunomodulatory
agents with this approach could potentially tune both systemic and
local immunity. Once the product candidates enter the development
stage, Boehringer Ingelheim will assume full responsibility for
development and PureTech Health will be eligible for various
developmental and sales milestones in addition to royalties on
product sales.
About PureTech's Lymphatic Targeting Platform
PureTech's proprietary lymphatic targeting platform is designed
to the body's natural lipid transport mechanisms to enable the
transport of drug molecules directly into the lymphatic system when
administered orally. This pathway facilitates entry into the
mesenteric lymph nodes, which are crucial centres for immune cell
priming, education and proliferation in the GI tract. Targeting the
lymphatic vasculature enables rational design of therapeutics to
modulate immunity in a tissue-specific manner and minimize systemic
toxicity due to global immunosuppression. Preclinical data suggest
PureTech's lymphatic targeting platform could potentially enable
more efficacious and less toxic therapeutics addressing cancer and
inflammatory and autoimmune diseases. This technology is based on
the pioneering research of Professor Chris Porter and his team at
the Monash Institute of Pharmaceutical Sciences, Monash University,
who continue to collaborate with PureTech Health on the programme.
All the relevant intellectual property associated with his work on
this technology is exclusively licensed to PureTech and is
supported by additional PureTech Health patents.
About PureTech Health
PureTech Health (LSE: PRTC) is an advanced biopharmaceutical
company developing BIG medicines for dysfunctions of the
Brain-Immune-Gut axis. The Company has gained deep insights into
the connection between these systems and the resulting role in
diseases that have proven resistant to established therapeutic
approaches. By harnessing this emerging field of human biology,
PureTech Health is developing new categories of medicines with the
potential to have great impact on people with serious diseases.
PureTech Health is advancing a rich pipeline of innovative
therapies with an unbiased, non-binary, and capital efficient
R&D model across its affiliates and its internal labs.
PureTech's affiliates include seven clinical-stage platforms,
including one product that has been cleared by the US Food and Drug
Administration (FDA) and a second product candidate that has been
filed with the FDA for review, and several other novel preclinical
programmes. The PureTech Health pipeline includes ground-breaking
platforms and therapeutic candidates that were developed in
collaboration with some of the world's leading experts.
PureTech's internal research and development is centred on
tissue-selective immunomodulation for the treatment of oncology,
autoimmune, and CNS-related disorders, with a near-term focus on
targeting newly-discovered, foundational immunosuppressive
mechanisms in oncology and novel approaches that harness the
lymphatic infrastructure.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
Contact:
Investors EU media U.S. media
Allison Mead Talbot Ben Atwell, Rob Winder Tom Donovan
+1 617 651 3156 +44 (0) 20 3727 1000 +1 857 559 3397
amt@puretechhealth.com ben.atwell@FTIconsulting.com tom@tenbridgecommunications.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCEAPLKFLFNEFF
(END) Dow Jones Newswires
April 17, 2019 02:00 ET (06:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024